SANTA CRUZ BIOTECHNOLOGY, INC.

AFX1 (E-17): sc-34899



BACKGROUND

FKHR (for forkhead in rhabdomyosarcoma), FKHRL1, and AFX1 are members of a subfamily of the forkhead family of transcription factors. AFX1, also known as Fox04, is expressed in a wide variety of tissues and, like other FKHR proteins, AFX1 contains a single forkhead domain and serine-proline-rich region, which mediate DNA binding. AFX1-mediated transcriptional activation is regulated by the serine/threonine kinase Akt1, which phosphorylates AFX1 and in turn, sequesters AFX1 in the cytosol, thereby blocking nuclear localization and DNA binding. Genetic mutations in FKHR genes, including the t(2;13) and t(1;3) translocations, are commonly found in alveolar rhabdo-myosarcomas. Additionally, the t(x;11) translocation of the AFX1 gene, which involves the fusion of a serine-proline-rich sequence of AFX1 to the carboxy-terminus of a truncated MLL, results in acute lymphocytic leukemia.

CHROMOSOMAL LOCATION

Genetic locus: MLLT7 (human) mapping to Xq13.1; MIIt7 (mouse) mapping to X C3.

SOURCE

AFX1 (E-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of AFX1 of human origin.

PRODUCT

Each vial contains 200 μ g lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Also available as TransCruz reagent for Gel Supershift and ChIP applications, sc-34899 X, 200 μ g/0.1 ml.

Blocking peptide available for competition studies, sc-34899 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

AFX1 (E-17) is recommended for detection of AFX1 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

AFX1 (E-17) is also recommended for detection of AFX1 in additional species, including equine and canine.

Suitable for use as control antibody for AFX1 siRNA (h): sc-29650, AFX1 siRNA (m): sc-29651, AFX1 shRNA Plasmid (h): sc-29650-SH, AFX1 shRNA Plasmid (m): sc-29651-SH, AFX1 shRNA (h) Lentiviral Particles: sc-29650-V and AFX1 shRNA (m) Lentiviral Particles: sc-29651-V.

AFX1 (E-17) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.


Molecular Weight of AFX1 isoforms: 54/48 kDa.

Positive Controls: BJAB nuclear extract: sc-2145, Jurkat nuclear extract: sc-2132 or Ramos nuclear extract: sc-2153.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

DATA



AFX1 (E-17): sc-34899. Western blot analysis of AFX1 expression in BJAB (**A**), Ramos (**B**), Jurkat (**C**) and Hen G2 (**D**) nuclear extracts

SELECT PRODUCT CITATIONS

 Noh, T.W., et al. 2009. Predicting recurrence of nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 94: 4406-4413.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

MONOS Satisfation Guaranteed